PURPOSE: National guidelines recommend that discussions about end-of-life (EOL) care planning happen early for patients with incurable cancer. We do not know whether earlier EOL discussions lead to less aggressive care near death. We sought to evaluate the extent to which EOL discussion characteristics, such as timing, involved providers, and location, are associated with the aggressiveness of care received near death. PATIENTS AND METHODS: We studied 1,231 patients with stage IV lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium, a population- and health system-based prospective cohort study, who died during the 15-month study period but survived at least 1 month. Our main outcome measure was the aggressiveness of EOL care received. RESULTS: Nearly half of patients received at least one marker of aggressive EOL care, including chemotherapy in the last 14 days of life (16%), intensive care unit care in the last 30 days of life (9%), and acute hospital-based care in the last 30 days of life (40%). Patients who had EOL discussions with their physicians before the last 30 days of life were less likely to receive aggressive measures at EOL, including chemotherapy (P = .003), acute care (P < .001), or any aggressive care (P < .001). Such patients were also more likely to receive hospice care (P < .001) and to have hospice initiated earlier (P < .001). CONCLUSION: Early EOL discussions are prospectively associated with less aggressive care and greater use of hospice at EOL.
PURPOSE: National guidelines recommend that discussions about end-of-life (EOL) care planning happen early for patients with incurable cancer. We do not know whether earlier EOL discussions lead to less aggressive care near death. We sought to evaluate the extent to which EOL discussion characteristics, such as timing, involved providers, and location, are associated with the aggressiveness of care received near death. PATIENTS AND METHODS: We studied 1,231 patients with stage IV lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium, a population- and health system-based prospective cohort study, who died during the 15-month study period but survived at least 1 month. Our main outcome measure was the aggressiveness of EOL care received. RESULTS: Nearly half of patients received at least one marker of aggressive EOL care, including chemotherapy in the last 14 days of life (16%), intensive care unit care in the last 30 days of life (9%), and acute hospital-based care in the last 30 days of life (40%). Patients who had EOL discussions with their physicians before the last 30 days of life were less likely to receive aggressive measures at EOL, including chemotherapy (P = .003), acute care (P < .001), or any aggressive care (P < .001). Such patients were also more likely to receive hospice care (P < .001) and to have hospice initiated earlier (P < .001). CONCLUSION: Early EOL discussions are prospectively associated with less aggressive care and greater use of hospice at EOL.
Authors: Craig C Earle; Elyse R Park; Bonnie Lai; Jane C Weeks; John Z Ayanian; Susan Block Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; Jeffrey M Souza; Jane C Weeks; Susan D Block; Eva Grunfeld; John Z Ayanian Journal: Int J Qual Health Care Date: 2005-06-28 Impact factor: 2.038
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Jennifer L Malin; Clifford Ko; John Z Ayanian; David Harrington; David R Nerenz; Katherine L Kahn; Julie Ganther-Urmie; Paul J Catalano; Alan M Zaslavsky; Robert B Wallace; Edward Guadagnoli; Neeraj K Arora; Maryse D Roudier; Patricia A Ganz Journal: Support Care Cancer Date: 2006-02-16 Impact factor: 3.603
Authors: Glenn Gade; Ingrid Venohr; Douglas Conner; Kathleen McGrady; Jeffrey Beane; Robert H Richardson; Marilyn P Williams; Marcia Liberson; Mark Blum; Richard Della Penna Journal: J Palliat Med Date: 2008-03 Impact factor: 2.947
Authors: Richard Brumley; Susan Enguidanos; Paula Jamison; Rae Seitz; Nora Morgenstern; Sherry Saito; Jan McIlwane; Kristine Hillary; Jorge Gonzalez Journal: J Am Geriatr Soc Date: 2007-07 Impact factor: 5.562
Authors: Daniel Hong; Lauren C Das; Ellen Daily; Stacie K Levine; Olwen M Hahn; Stanley L Liauw; Daniel W Golden; Christina H Son Journal: Support Care Cancer Date: 2021-05-25 Impact factor: 3.603
Authors: Daneng Li; Ghassan K Abou-Alfa; Aaron D Viny; Meredith Cammarata; Ali Shamseddine; Ashwaq Al-Olayan; Hibah Osman; Ali Haydar; Ghassan Kanazi; Mohamed Naghy; Eileen M O'Reilly; Andrew S Epstein Journal: J Gastrointest Oncol Date: 2015-10